ACP
VCYT icon

Acuta Capital Partners’s Veracyte VCYT Stock Holding History

Acuta Capital Partners’s Portfolio VCYT Stock Details VCYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-160,000
Closed -$1.33M – 77
2017
Q2 		$1.33M Buy
160,000
+30,000
+23% +$245K 0.37% 41
2017
Q1 		$1.19M Sell
130,000
-245,000
-65% -$2M 0.28% 48
2016
Q4 		$2.9M Buy
+375,000
New +$2.8M 1.08% 23

Other funds holding VCYT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Acuta Capital Partners's VCYT Position: Q4 2019 in Review

Acuta Capital Partners sold out of Veracyte (VCYT) in Q4 2019, closing a stake of 112,500 shares — an estimated $2.7M sold.

Acuta Capital Partners first reported a position in VCYT in Q4 2014 and held it in 19 quarters. The position peaked at $28.9M in Q3 2017. 179 funds tracked by Wall St. Rank hold VCYT as of Q4 2019.

  • Acuta Capital Partners reported no remaining Veracyte position as of Q4 2019 after selling out during the quarter.
  • Acuta Capital Partners sold 112,500 Veracyte shares in Q4 2019, an estimated $2.7M.
  • Acuta Capital Partners first reported a position in Veracyte in Q4 2014 and held it in 19 quarters.
  • Acuta Capital Partners's Veracyte position peaked at $28.9M in Q3 2017.
  • 179 funds tracked by Wall St. Rank held Veracyte as of Q4 2019.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.